Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells <i>in vitro</i>
- DOI
- 10.1002/ijc.20917
- Published
- 2005-04-18
- Container
- International Journal of Cancer
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.20917,
title = {Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells <i>in vitro</i>},
author = {Claudio Festuccia and Giovanni Luca Gravina and Adriano Angelucci and Danilo Millimaggi and Paola Muzi and Carlo Vicentini and Mauro Bologna},
year = {2005},
journal = {International Journal of Cancer},
doi = {10.1002/ijc.20917},
url = {https://doi.org/10.1002/ijc.20917}
}RIS
TY - JOUR TI - Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells <i>in vitro</i> AU - Claudio Festuccia AU - Giovanni Luca Gravina AU - Adriano Angelucci AU - Danilo Millimaggi AU - Paola Muzi AU - Carlo Vicentini AU - Mauro Bologna PY - 2005 JO - International Journal of Cancer DO - 10.1002/ijc.20917 UR - https://doi.org/10.1002/ijc.20917 ER -
APA
Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C., & Bologna, M. (2005). Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells <i>in vitro</i>. International Journal of Cancer. https://doi.org/10.1002/ijc.20917
Source records
- crossref · retrieved 2026-09-25T00:06:55.287Z